Mandatory surveillance of bacteremia conducted by automated monitoring.

Journal: Frontiers in public health
PMID:

Abstract

Except for a few countries, comprehensive all-cause surveillance for bacteremia is not part of mandatory routine public health surveillance. We argue that time has come to include automated surveillance for bacteremia in the national surveillance systems, and explore diverse approaches and challenges in establishing bacteremia monitoring. Assessed against proposed criteria, surveillance for bacteremia should be given high priority. This is based on severity, burden of illness, health gains obtained by improved treatment and prevention, risk of outbreaks (including health care associated infections), the emergence of antimicrobial drug resistance as well as the changing epidemiology of bacteremia which is seen along with an aging population and advances in medical care. The establishment of comprehensive surveillance for bacteremia was until recently conceived as an insurmountable task. With computerized systems in clinical microbiology, surveillance by real-time data capture has become achievable. This calls for re-addressing the question of including bacteremia among the conditions under mandatory surveillance. Experiences from several countries, including Denmark, show that this is feasible. We propose enhanced international collaboration, legislative action, and funding to address the challenges and opportunities.

Authors

  • Kåre Mølbak
    Epidemiological Infectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark.
  • Christian Østergaard Andersen
    Department of Diagnostic and Infectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark.
  • Ram B Dessau
    Department of Data Integration and Analysis, Statens Serum Institut, Copenhagen, Denmark.
  • Svend Ellermann-Eriksen
    Department of Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark.
  • Sophie Gubbels
    Department of Data Integration and Analysis, Statens Serum Institut, Copenhagen, Denmark.
  • Thøger Gorm Jensen
    Department of Clinical Microbiology, Odense University Hospital, Odense, Denmark.
  • Jenny Dahl Knudsen
    Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.
  • Brian Kristensen
    Department of Infectious Diseases Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark.
  • Lisbeth Lützen
    Department of Clinical Microbiology, Sygehus Lillebælt, Vejle, Denmark.
  • John Coia
    Research Unit of Clinical Microbiology, Department of Regional Health Research, Esbjerg, Denmark.
  • Bente Ruth Scharvik Olesen
    Department of Clinical Microbiology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
  • Mette Pinholt
    Department of Clinical Microbiology, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark.
  • Flemming Scheutz
    Department of Bacteria, Parasites and Fungi, The International Escherichia and Klebsiella Centre, Statens Serum Institut, Copenhagen, Denmark.
  • Ute Wolff Sönksen
    Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark.
  • Kirstine K Søgaard
    Department of Clinical Microbiology, Aalborg University Hospital, Aalborg, Denmark.
  • Marianne Voldstedlund
    Department of Data Integration and Analysis, Statens Serum Institut, Copenhagen, Denmark.